What is the amount and purpose of AstraZeneca's newly announced investment in the UK, according to Prime Minister Keir Starmer?

According to Prime Minister Keir Starmer, AstraZeneca will invest £300 million ($405 million) in UK life sciences, a move he said was made possible by the pharmaceutical arrangement the UK has struck with the United States. The investment is intended to future-proof 1,000 jobs in Macclesfield and Cambridge.

Why did AstraZeneca previously pause or cancel major UK projects, and how does the new investment relate to recent policy changes?

AstraZeneca had paused large-scale projects in Britain last year, citing an unfavourable business environment — including scrapping a proposed £450-million vaccine manufacturing plant in northern England after a cut in government support, and scaling back a £200-million investment plan in Cambridge. The new £300-million investment follows praise from drugmakers, including AstraZeneca, for the US–UK pharmaceutical deal, which aligns UK medicine pricing with the Trump administration’s US pricing policies under the ‘most-favoured-nations’ framework — a policy environment they say risks Europe missing out on new medicines.

AstraZeneca plans to invest $405 million in Britain, PM Starmer says

Apr 29, 2026

Prime Minister Keir Starmer announced AstraZeneca will invest £300 million ($405 million) in UK life sciences following a new US-UK pricing agreement. This investment secures 1,000 jobs in Macclesfield and Cambridge after the company previously paused projects due to regulatory concerns.

reuters

2026-04-29

AstraZeneca plans to invest $405 million in Britain, PM Starmer says

AstraZeneca plans to invest $405 million in Britain, PM Starmer says

FAQ